KRAS and neoplasm: KRAS mutations promote tumor cell proliferation and survival by activating key signaling pathways, including the PI3K/Akt and MAPK pathways, and modulating the cellular response to chemotherapy, often by reducing drug-induced apoptosis or altering drug metabolism [4, 5].